Results from the PURE-01 trial show a durable 5-yr overall survival rate (77.4%) in muscle-invasive bladder cancer after neoadjuvant pembrolizumab and a correlation between pathological responses and survival outcomes. The claudin-low molecular subtype identifies patients especially responsive to immune checkpoint inhibitor monotherapy.
Results from the PURE-01 trial show a durable 5-yr overall survival rate (77.4%) in muscle-invasive bladder cancer after neoadjuvant pembrolizumab and a correlation between pathological responses and survival outcomes. The claudin-low molecular subtype identifies patients especially responsive to immune checkpoint inhibitor monotherapy.